The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of CVm-Health app in the US

19 May 2020 16:00

RNS Number : 3871N
Sensyne Health PLC
19 May 2020
 

 

Clinical AI leader Sensyne Health launches CVm-Health™ 'Good Neighbor' app in the United States with support from Microsoft and Cognizant

 

New COVID-19 web-based app helps people record their health status and symptoms and do the same for family and friends

 

Highlights:

· CVm-Health is a free, easy to use web-based software application now available in the US

· Enables the recording of health conditions, symptoms, vital signs and medications, creating a health diary that can be shared with healthcare professionals

· Empowers people to help family or friends who do not have access to the internet monitor their health

· The CVm-Health app was developed with support from Microsoft and Cognizant and is part of a broader strategy by Sensyne Health to provide a platform that enables the delivery of care to patients remotely

 

Oxford, U.K. May 19,2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI technology company, today announces the US launch of its web-based COVID-19 focused software application called CVm-Health - the 'Good Neighbor' app. CVm-Health was successfully rolled out in the UK in April 2020.

 

CVm-Health US app - launched today

Today's launch of CVm-Health in the US coincides with the start of the Microsoft Build conference, where the app will be highlighted https://youtu.be/FIOPM6TiOmg 

 

The app is free to use for anyone in the US and provides a secure way for individuals to manage their health by recording their vital signs daily and any COVID-19 related symptoms.

 

The app also enables individuals to help family and friends who are digitally disconnected and at risk from coronavirus to monitor their health. In 2019 the Pew Research Center found that 10% of all Americans and 27% of Americans over 65 don't use the internet, and many of these people are in higher-risk categories for COVID-19.

 

Subject to individuals consent, data generated by the application will be de-identified and analyzed using sophisticated machine learning techniques to derive insights that will be made available for medical research into the prevention, diagnosis and treatment of COVID-19.

The app was developed with the support of Cognizant and Microsoft. Sensyne announced its partnership with Cognizant in October 2019 to accelerate the development of its applications specifically for the US market. Microsoft is Sensyne's chosen provider of world-class IT infrastructure services, including its Azure® suite of cloud services, which enable Sensyne's clinical applications to be scaled globally.

 

Lord (Paul) Drayson, CEO of Sensyne Health, said:

"We wanted to provide an app that helped everyone to record and self-monitor their symptoms and take control of their own health, as well as helping others."

 

 

CVm-Health is available to use at www.CVm-Health.com

 

-ENDS-

 

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Michael Norris, Interim Chief Financial Officer

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden

James Steel

Oliver Jackson

Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma

Euan Brown

Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

sensynehealth@consilium-comms.com

Consilium Strategic Communications US

001 617-680-1088

Paul Kidwell

kidwell@consilium-comms.com

 

About Sensyne Health

 

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organizations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKCBBQBKDQPD
Date   Source Headline
19th Aug 20202:00 pmRNSPrice Monitoring Extension
19th Aug 20207:00 amRNSDevelopment of ‘DBm-Health™’ for diabetes
17th Aug 20204:41 pmRNSSecond Price Monitoring Extn
17th Aug 20204:36 pmRNSPrice Monitoring Extension
13th Aug 20202:06 pmRNSSecond Price Monitoring Extn
13th Aug 20202:00 pmRNSPrice Monitoring Extension
10th Aug 20207:00 amRNSSensyne Health settles employment tribunal claim
20th May 202011:05 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
19th May 20204:00 pmRNSLaunch of CVm-Health app in the US
14th May 20207:00 amRNSTrading and Business Update
5th May 20207:00 amRNSSensyne Health launches BPm-Health product
20th Apr 20207:00 amRNSLaunch of CVm-Health ‘Good Neighbour’ app
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
30th Mar 20202:05 pmRNSSecond Price Monitoring Extn
30th Mar 20202:00 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
27th Mar 20202:52 pmRNSGDm-Health free to NHS in response to COVID-19
11th Mar 20209:00 amRNSHolding(s) in Company
2nd Mar 20205:29 pmRNSInterim Chief Financial Officer appointment
2nd Mar 20208:18 amRNSDirectorate Change
28th Feb 20204:00 pmRNSHSJ Partnership Award for GDm-Health
3rd Feb 20207:00 amRNSHoldings in Company
21st Jan 20207:00 amRNSSensyne Health confirms benefits in study
21st Jan 20207:00 amRNSSensyne Health Interim Results
16th Jan 20202:05 pmRNSSecond Price Monitoring Extn
16th Jan 20202:00 pmRNSPrice Monitoring Extension
23rd Dec 20197:00 amRNSSensyne Health enters AI research collaboration
20th Dec 20199:00 amRNSNotice of Results
16th Dec 20197:00 amRNSUpdate Following General Election
10th Dec 20197:00 amRNSBoard Changes
15th Nov 20197:00 amRNSCognizant and Agorai named as partners
30th Oct 20192:28 pmRNSResult of AGM
30th Oct 20197:41 amRNSDirectorate Change
22nd Oct 20197:00 amRNSAppointment of Joint Broker and Financial Adviser
22nd Oct 20197:00 amRNSRemuneration Policy and Corporate Governance
17th Oct 20195:21 pmRNSHolding(s) in Company
15th Oct 20195:16 pmRNSHolding(s) in Company
10th Oct 20197:00 amRNSSensyne extends partnership with Bayer
7th Oct 20197:00 amRNSAnnual Report and Accounts
7th Oct 20197:00 amRNSCollaboration with UK MHRA
7th Oct 20197:00 amRNSMajor Agreements for digital health products in US
7th Oct 20197:00 amRNSSensyne Health Maiden Full Year Results
4th Oct 20197:00 amRNSBoard Change
4th Oct 20197:00 amRNSRelated party transactions
23rd Sep 201912:00 pmRNSBoard Change
12th Sep 20197:00 amRNSNotice of Full Year Results
2nd Aug 201912:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.